

## Data Sharing Statement

| Article Info | <a href="https://dx.doi.org/10.21037/atm-22-1442">https://dx.doi.org/10.21037/atm-22-1442</a>   |   |
|--------------|---|---|
| Item         | Question  | Authors' Response<br>(place "-" if not applicable)  |
| 1            | Would you like to share data collected for your study to others?  | Yes.  |
| 2            | If not, would you like to share the reason for your decision?   | -   |
| 3            | What data in particular will be shared?   | The data of VEGFR-2, CD31, and Ki-67, $\gamma$ -H2AX, apoptosis, tumor metabolism and volume will be shared.            |
| 4            | Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code. | Statistical analysis plan, detection and determination criteria of VEGFR-2, CD31, and Ki-67, $\gamma$ -H2AX, apoptosis. |
| 5            | When will data availability begin?  | From the publication date.  |
| 6            | When will data availability end?  | Two years within the publication date.  |
| 7            | To whom will you share the data?  | Medical oncologists and cervical cancer radiotherapy physician.   |
| 8            | For what type of analysis or purpose?   | Radiotherapy combined with anti-angiogenesis therapy for cervical cancer.   |
| 9            | How or where can the data/documents be obtained?  | Emails could be sent to the address below to obtain the shared data: zhangjianwen66@126.com                             |
| 10           | Any other restrictions?   | We may balance the potential benefits and risks for each request and then provide the data that could be shared.        |